Almirall, S.A. Announces Promotion of Pablo Alvarez as President of Almirall US
November 11, 2020 at 03:00 am EST
Share
Almirall, S.A. has announced that Pablo Alvarez has been promoted and will become the new President & GM of Almirall US, reporting directly to the CEO and serving on the Management Board effective November 11, 2020. Pablo has previously served as Commercial Operations Director, overseeing several market companies such as the UK, Netherlands, Nordics, Belgium and France, as well as heading a number of global functions during which he gained extensive experience in medical dermatology. The company would like to thank Ron Menezes for his work and dedication to the company during the last 3 years.
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
ALMIRALL, S.A. 
